SIMPONI is designed to treat moderately to severely active UC in patients who have not responded well to past conventional therapies. It is the first and only subcutaneous anti-tumor necrosis factor alpha treatment administered every four weeks for UC therapy.
More Articles on Gastroenterology:
GlaxoSmithKline Returns Drug Rights to ChemoCentryx After Failed Trial
5 Recent GI Center Openings, Plans & Expansions
“S” or “C” Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
